CN1977878A - Chinese medicine composition and its use - Google Patents
Chinese medicine composition and its use Download PDFInfo
- Publication number
- CN1977878A CN1977878A CNA2005101228228A CN200510122822A CN1977878A CN 1977878 A CN1977878 A CN 1977878A CN A2005101228228 A CNA2005101228228 A CN A2005101228228A CN 200510122822 A CN200510122822 A CN 200510122822A CN 1977878 A CN1977878 A CN 1977878A
- Authority
- CN
- China
- Prior art keywords
- group
- chinese medicine
- extract
- medicine composition
- radix rhodiolae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The present invention relates to a Chinese medicine composition. Said Chinese medicine composition is made up by using (by wt%) 1%-99% of rhodiola root or rhodiola root extract and 99%-1% of ginkgo leaf or ginkgo leaf extract. Said Chinese medicine composition can be used for preventing and curing angiocardiopathy and cerebrovascular disease.
Description
Technical field
The present invention relates to a kind of is the pharmaceutical composition of raw material with the Chinese herbal medicine, particularly a kind of Chinese medicine composition for the treatment of multiple disease.The invention still further relates to the purposes of this kind Chinese medicine composition.
Background technology
Radix Rhodiolae is Crassulaceae rhodiola (RhodiolaL.) herbaceos perennial, generally be grown in high and cold, dry, anoxia, strong ultraviolet radiation, high height above sea level area that day and night temperature is big, have extremely strong environmental suitability and indomitable vitality, Radix Rhodiolae is with root and rhizome, or with all herbal medicine, so far the medicinal history in existing more than 1000 year because of its unique drug effect, is described as " Radix Et Rhizoma Fagopyri Tatarici ", " plateau Radix Ginseng ".Shennong's Herbal and " four pharmacopeia " are all on the books, classify top grade medicine as, can be used for strengthening by means of tonics, allaying tiredness, the cold resisting.The underground root stock of Radix Rhodiolae Chang Yiqi is used as medicine, its main effective ingredient be salidroside (rhodioside, salidroside) and tyrosol (tyrosol).Rhodioside is a kind of important active component, often estimates the Rhodida plant medical value with its content.
Folium Ginkgo is the leaf of Ginkgoaceae Ginkgo plant Ginkgo biloba Ginkgo biloba L., has another name called Gong Sunshu, is to have one of Relict Plant in ancient times now, is the special product of China plant.Since the sixties, Chinese scholars has been done number of research projects to the chemistry of Semen Ginkgo, pharmacological action etc., find to be rich in ginkgetin, bilobalide in the Folium Ginkgo, wherein bilobalide has high degree of specificity PAF antagonistic activity [Highly Specificantagonists of platelet activation factor (PAF)] and causes the common concern of Chinese scholars.Because PAF participates in many pathophysiological processes, act on widely, and activity is very big.
Summary of the invention
Technical problem to be solved by this invention is at the deficiencies in the prior art, provides a kind of prescription simple, reasonable, the significant Chinese medicine composition of drug effect of compatibility.
The present invention also provides the purposes of above-mentioned Chinese medicine composition.
Technical problem to be solved by this invention is to realize by following technical scheme.The present invention is a kind of Chinese medicine composition, it is characterized in that, it is the medicament of being made by following raw materials by weight percent:
Radix Rhodiolae or Radix Rhodiolae extract 1%～99%;
Folium Ginkgo or Folium Ginkgo extract 99%～1%.
Radix Rhodiolae extract that the present invention is alleged and Folium Ginkgo extract are meant commercially available Radix Rhodiolae extract and Folium Ginkgo extract, or raw material Radix Rhodiolae, Folium Ginkgo extract the Radix Rhodiolae extract and the Folium Ginkgo extract of gained by disclosed any technology in the prior art.
The dosage form of Chinese medicine composition of the present invention can be selected said any dosage form on the pharmaceutics for use, comprise tablet, capsule, soft capsule, spray, gel, gel inhalant, oral agents, suspensoid, electuary, patch, ointment, pill, powder, injection, infusion solution, freeze dried injection, lipidosome injection, target administration injection, suppository, slow releasing preparation or controlled release preparation.
Technical problem to be solved by this invention can also further realize by following technical scheme.Above-described a kind of Chinese medicine composition is characterized in, rhodioside, butyl alcohol content in Radix Rhodiolae extract is not less than 10% in the Radix Rhodiolae extract.
Technical problem to be solved by this invention can also further realize by following technical scheme.Above-described a kind of Chinese medicine composition is characterized in, rhodioside, butyl alcohol content in Radix Rhodiolae extract is not less than 50% in the Radix Rhodiolae extract.
Technical problem to be solved by this invention can also further realize by following technical scheme.Above-described a kind of Chinese medicine composition is characterized in that Folium Ginkgo extract contains Ginkgo total flavones, bilobalide, and wherein bilobalide content in Folium Ginkgo extract is not less than 6%.
Technical problem to be solved by this invention can also further realize by following technical scheme.Above-described a kind of Chinese medicine composition is characterized in, wherein, bilobalide content in Folium Ginkgo extract is not less than 90%.
Chinese medicine composition of the present invention can be used for preparing the medicine of treatment alzheimer disease, apoplexy, angina pectoris, diabetic microvascular complication, viral myocarditis, infectious hepatitis and tumor.
The algoscopy of rhodioside, butyl alcohol is as follows in the Chinese medicine composition of the present invention:
(1) chromatographic condition; Chromatographic column: with octadecylsilane chemically bonded silica is filler; Mobile phase: water one methanol one second eyeball 70: 25: 5; Flow velocity: 0.5ml/min; Detect wavelength 275nm;
(2) preparation of reference substance solution; Precision takes by weighing 105 ℃ of rhodioside, each 5mg of butyl alcohol reference substance of being dried to constant weight, puts in the 10mL measuring bottle, with dissolve with methanol and be diluted to scale, shakes up, promptly;
(3) preparation of need testing solution; Precision takes by weighing 105 ℃ of this product 10mg that are dried to constant weight and puts in the 10mL measuring bottle, with dissolve with methanol and be diluted to scale, shakes up, promptly;
(4) algoscopy; Precision is measured need testing solution and each 20 μ L of reference substance solution, injects chromatograph of liquid respectively, measures, promptly;
The algoscopy of bilobalide is as follows in the Chinese medicine composition of the present invention:
(1) chromatographic condition and system suitability experiment; With octadecylsilane chemically bonded silica is filler, with isopropyl alcohol-methanol-water is mobile phase at 8: 24: 80, detect wavelength 220nm, theoretical cam curve should be not less than 7000 by ginkalide B, and ginkalide B and adjacent peak-to-peak separating degree and tailing factor should meet the requirements;
(2) preparation of reference substance solution; Precision takes by weighing 105 ℃ of ginkalide A, each 10mg of B reference substance of being dried to constant weight, puts in the 10mL measuring bottle, with 50% acetone solution and be diluted to scale, shakes up, promptly;
(3) preparation of need testing solution; Precision takes by weighing 105 ℃ of this product 20mg that are dried to constant weight and puts in the 10mL measuring bottle, with 50% acetone solution and be diluted to scale, shakes up, promptly;
(4) algoscopy; Precision is measured need testing solution and each 20 μ L of reference substance solution, injects chromatograph of liquid respectively, measures, promptly.
The present invention adopts Radix Rhodiolae or its extract and Folium Ginkgo or its extract composition compound recipe, can be from ischemic myocardial protection, the protection of infraction brain cell, and aspect synergism such as PAF antagonism have the higher drug curative effect.Present composition prescription is simple, compatibility is reasonable, and is quality controllable.
The pharmacodynamic study of the following compositions that the inventor did.
(1), compositions 8,20,50mg/kg iV can make the apoplexy scoring of MCAO rat reduce, the MCAO infarction size dwindles, brain water content reduces (P＜0.01), its action intensity significantly is better than the Ginaton injection.
(2), compositions 8,20,50mg/kg iV can make the MDA in the cerebral tissue of focal cerebral ischemia rat reperfusion injury, the LA equal size reduces (P＜0.01), shows that cerebral tissue hypoxic-ischemic and peroxidating degree are subjected to obvious inhibition; SOD and GSH content increase (P＜0.01) simultaneously, have reflected that medicine has raising to antioxidant ability of organism and the ability of removing free radical.
(3), compositions 8,20,50mg/kg iV can obviously protect the cerebral tissue structure of focal cerebral ischemia rat reperfusion injury; karyopycnosis, the karyolysis degree of cerebral cortex pyramidal cell and brain essence neurocyte obviously alleviate than ischemic control group, and softening kitchen range reduces.
(4), compositions 8,20,50mg/kg iV compare with model group that the EEG that can make diffusivity global brain ischemia rat recovers normal time and recovery time is obviously shortened (P＜0.01) in righting reflex, makes the azovan blue permeability significantly reduce (P＜0.01).
(5), composition I v8min promptly begins onset, about peak time 18min, the persistent period can reach more than the 100min; And this medicine ig onset time 20-25min, about peak time 40min, the persistent period can reach more than the 120min.The effect of same dosage group iV is better than ig.
(6) but, compositions 20,40, the time-to-live (P＜0.01) of 80mg/kg iV significant prolongation mice under anaerobic condition.
(7), compositions 3,6,12mg/ml induce the rabbit extracorporeal platelet aggregation that obvious inhibitory action (P＜0.01) is all arranged to PAF, and obvious depolymerisation (P＜0.01) are arranged.To ADP induced platelet aggregation weak (P＜0.05 or P＜0.01), there is not obvious depolymerisation (P＞0.05).This medicine iV2.5,5,10mg/kg all have obvious inhibitory action (P＜0.01) to platelet aggregation in the inductive rabbit body of PAF, and middle and high dosage group also has obvious depolymerisation (P＜0.01).The rabbit platelet number there is not obvious effect (P＞0.05).
(8), it is moving that compositions iv 3,6,12mg/kg can obviously suppress rabbit---the thrombosis (P＜0.01) of vein bypass.
(9), compositions iv 6,12,24mg/kg are moving to rat---and vein bypass thrombosis has obvious thrombolytic effect (P＜0.01).
(10), just can obviously suppress PAF behind the compositions iv 6mg/kg medicine immediately induces and exempts from the body platelet aggregation and obvious depolymerisation (P＜0.01) is arranged, effect continues 35min, be 5min during its peak, platelet aggregation inhibition rate can reach about 79%, and depolymerization in 1 minute is about 85%.30min can obviously suppress PAF and induces in the rabbit body platelet aggregation and obvious depolymerisation (P＜0.01) is arranged behind the compositions ig15mg/kg medicine, continue 75min, be about 42min during its peak, the maximum gathering of platelet suppression ratio is about 48%, and the depolymerization rate was about 45% in 1 minute.
(11) influence of alzheimer disease rat model.
11.1 influence to ability of learning and memory and space exploration ability.The result shows, along with the increase of training natural law, all shorten each incubation period of organizing rat, respectively organizes rat there was no significant difference incubation period on the the 1st, 2 two day, begins to occur significant difference on the 3rd day.Model group relatively obviously prolongs with blank group incubation period, and the number of times of crossing over platform reduces (P＜0.01); Significantly be shorter than model group, significant difference (P＜0.01) incubation period that gastric infusion is respectively organized rat.Experimental result sees Table 1.
Table 1 pair water maze laboratory incubation period and the influence of crossing over the platform number of times
| Group | The example number | The 3rd day (latent time, the min of unit) | The 4th day (latent time, the min of unit) | The 5th day (latent time, the min of unit) | The 6th day (crossing over the platform number of times) |
| Dosage group composition high dose group in the false damage group of the blank group AD model group donepezil group composition low dose group composition | 10 10 10 10 10 10 10 | 20.4±9.2 50.8±10.4 △△ 34.8±9.6 ** 22.3±6.9 ** 26.7±8.4 ** 23.3±9.0 ** 21.8±11.1 ** | 16.4±9.4 48.3±10.3 △△ 33.0±9.4 ** 19.4±8.0 ** 24.7±8.0 ** 21.6±9.3 ** 20.1±11.2 ** | 14.5±8.7 44.1±10.7 △△ 29.6±10.7 * 17.4±8.5 ** 21.5±9.1 ** 19.4±10.2 ** 18.4±10.8 ** | 3.8±1.0 0.5±0.5 △△ 1.7±1.4 ** 2.9±1.7 ** 2.1±2.2 * 2.2±1.4 ** 2.7±1.7 ** |
Annotate: compare with the blank group,
△ △P＜0.01.Compare with the AD model group,
*P＜0.05,
*P＜0.01.
11.2 to SOD activity in the alzheimer disease rat model cerebral tissue, the influence of MDA content
The result shows, the relatively active obviously reduction of SOD of AD model group and blank group, and MDA content raises, (P＜0.01); Gastric infusion is respectively organized rat SOD activity and is compared the rising that all has in various degree with the AD model group, and MDA content all has in various degree reduction and AD model group to compare significant difference.The results are shown in Table 2.
SOD activity in the table 2 pair alzheimer disease rat model cerebral tissue, the influence of MDA content
| Group | The example number | Dosage (mg/kg) | SOD | MDA |
| Dosage group high dose group in the false damage group of the blank group AD model group donepezil group composition low dose group | 10 10 10 10 10 10 10 | - - - 0.018 | 192.5±11.2 135.2±10.5 △△ 170.6±9.35 ** 176.4±12.6 ** 160.2±14.0 ** 173.5±10.5 ** 183.4±9.69 ** | 1.4±0.2 3.1±0.6 △△ 2.1±0.7 ** 1.9±0.4 ** 2.0±0.3 ** 1.7±0.4 ** 1.6±0.3 ** |
Annotate: compare with the blank group,
△ △P＜0.01.Compare with the AD model group,
*P＜0.05,
*P＜0.01.
(12) to influence to senile dementia rat hippocampus neurotransmitter.
Model group Hippocampus Ach content significantly is lower than false damage group, significant difference (P＜0.01); After the medicine filling stomach treatment through 20d, each medicine group Hippocampus Ach content of gastric infusion all is higher than model group, has significant difference (P＜0.01).The results are shown in Table 3.
The influence of table 3 couple rat hippocampus Ach, 5-HT and NE content
| Group | The example number | Dosage (mg/kg) | Ach(mg/g) | 5-HT(ng/g) | NE(ng/g) |
| The AD model group | 10 | - | 0.8±0.3 | 87.6±12.6 | 78.4±19.5 |
| False damage group | 10 | - | 3.1±0.4 △△ | 284.6±26.1 △△ | 442.6±23.4 △△ |
| The donepezil group | 10 | 0.018 | 2.3±0.5 ** | 210.3±26.4 ** | 281.6±22.4 ** |
| The compositions low dose group | 10 | 1.7±0.5 ** | 185.2±19.1 ** | 224.5±26.3 ** | |
| Dosage group in the compositions | 10 | 2.1±0.3 ** | 209.2±23.2 ** | 251.3±21.2 ** | |
| The compositions high dose group | 10 | 2.8±0.6 ** | 243.6±16.0 ** | 326.4±20.7 ** |
Annotate: compare with the blank group,
△ △P＜0.01.Compare with the AD model group,
*P＜0.05,
*P＜0.01.
(13) to the influence of mice senile dementia model.
13.1 the influence to senile dementia mice active learning and memory: compare with the normal control group, model control group mice test phase is initiatively avoided incubation period (T1) and is initiatively avoided number of times (N1) and obviously reduce, and passive avoidance incubation period (Ts) and passive avoidance number of times (Ns) obviously increase, have significant statistical significance (P＜0.01), show senile dementia model modeling success; With model control group relatively, ig administration group can significantly raise (T1) and (N1), reduction (Ts) and (Ns), significant difference (P＜0.01).The results are shown in Table 4.
The initiatively influence of learning and memory of table 4 pair senile dementia mice
N=10)
| Group | Dosage (g/kg) | Tested first day | |||
| T(sec) | Ts(sec) | N | Ns | ||
| Dosage group high dose group in the normal control group model matched group Ginkgo Biloba Leaf Preparation group low dose group | - - 0.012 | 2.2±0.5 1.6±0.4 △△ 2.2±0.6 * 1.8±0.4 2.1±0.5 * 2.4±0.5 ** | 3.1±0.3 3.9±0.2 △△ 2.9±0.3 ** 3.5±0.4 * 3.3±0.5 ** 2.8±0.5 ** | 1.2±0.3 0.9±0.2 △ 1.9±0.3 ** 1.0±0.1 1.3±0.1 ** 1.5±0.3 ** | 9.5±0.6 10.3±0.6 △△ 6.6±0.9 ** 9.0±0.6 ** 8.2±0.5 ** 7.3±0.5 ** |
Annotate: compare with the blank group,
△P＜0.05,
△ △P＜0.01.Compare with the AD model group,
*P＜0.05,
*P＜0.01.
13.2 influence to senile dementia mouse blood SOD, MDA and MAO content.
Compare with normal group, obviously increase, do not see remarkable meaning though the MAO content of model group mice significantly improves MDA content; SOD does not have obvious change.After the ig administration, the administration group can significantly reduce MAO content, in, heavy dose of group also has remarkable reduction to MDA content, but the SOD level do not had obvious influence.The results are shown in Table 5.
Table 5 couple senile dementia mouse blood SOD, MDA and MAO contain influence
| Group | Dosage | The example number | SOD(μg/gHB) | MDA(μmol/L) | MAO(10-3U/L) |
| The normal control group | - | 10 | 275.2±29.3 | 3.6±0.3 | 39.0±3.2 |
| Model control group | - | 10 | 259.1±27.6 | 3.7±0.2 | 43.5±3.1 △△ |
| The Ginkgo Biloba Leaf Preparation group | 0.012 | 10 | 275.2±23.1 | 3.5±0.3 | 38.6±4.1 ** |
| Low dose group | l0 | 261.6±35.7 | 3.5±0.3 | 40.5±4.1 ** | |
| Middle dosage group | 10 | 265.8±37.3 | 3.3±0.4 ** | 38.6±3.0 ** | |
| High dose group | 10 | 270.4±24.1 | 3.3±0.3 ** | 37.1±2.4 ** |
Annotate: compare with the blank group,
△P＜0.05,
△ △P＜0.01.Compare with the AD model group,
*P＜0.05,
*P＜0.01.
The specific embodiment
Embodiment 1.A kind of Chinese medicine composition, it is the medicament of being made by following raw materials by weight percent:
Radix Rhodiolae 1%; Folium Ginkgo 99%.
Its preparation method is that technology is extracted its active ingredient routinely, adds conventional pharmaceutic adjuvant, makes tablet according to a conventional method, is used for the treatment of alzheimer disease.
Embodiment 2.A kind of Chinese medicine composition, it is the medicament of being made by following raw materials by weight percent:
Radix Rhodiolae 99%; Folium Ginkgo 1%.
Its preparation method is that technology is extracted its active ingredient routinely, adds conventional pharmaceutic adjuvant, makes granule according to a conventional method, is used for apoplexy.
Embodiment 3.A kind of Chinese medicine composition, it is the medicament of being made by following raw materials by weight percent:
Radix Rhodiolae 50%; Folium Ginkgo 50%.
Its preparation method is that technology is extracted its active ingredient routinely, adds conventional pharmaceutic adjuvant, makes capsule according to a conventional method, is used for the treatment of angina pectoris.
Embodiment 4.A kind of Chinese medicine composition, it is the medicament of being made by following raw materials by weight percent:
Radix Rhodiolae extract 1%; Folium Ginkgo extract 99%.
Its preparation method is, adds conventional pharmaceutic adjuvant, makes injection according to a conventional method, is used for diabetic microvascular complication.
Embodiment 5.A kind of Chinese medicine composition, it is the medicament of being made by following raw materials by weight percent:
Radix Rhodiolae extract 99%; Folium Ginkgo extract 1%.
Its preparation method is, adds conventional pharmaceutic adjuvant, makes lyophilized injectable powder according to a conventional method, is used for the treatment of viral myocarditis.
Embodiment 6.A kind of Chinese medicine composition, it is the medicament of being made by following raw materials by weight percent:
Radix Rhodiolae extract 50%; Folium Ginkgo extract 50%.
Its preparation method is, adds conventional pharmaceutic adjuvant, makes electuary according to a conventional method, is used for the treatment of infectious hepatitis.
Embodiment 7.A kind of Chinese medicine composition, it is the medicament of being made by following raw materials by weight percent:
Radix Rhodiolae extract 10%; Folium Ginkgo extract 90%.
Its preparation method is, adds conventional pharmaceutic adjuvant, makes soft capsule according to a conventional method, is used for the treatment of tumor.
Embodiment 8.A kind of Chinese medicine composition, it is the medicament of being made by following raw materials by weight percent:
Radix Rhodiolae extract 90%; Folium Ginkgo extract 10%.
Its preparation method is, adds conventional pharmaceutic adjuvant, makes powder according to a conventional method.
Embodiment 9.A kind of Chinese medicine composition, it is the medicament of being made by following raw materials by weight percent:
Radix Rhodiolae 15%; Folium Ginkgo extract 85%.
Its preparation method is that technology extracts the active ingredient of Radix Rhodiolae routinely, adds Folium Ginkgo extract, adds conventional pharmaceutic adjuvant again, makes tablet according to a conventional method.
Embodiment 10.A kind of Chinese medicine composition, it is the medicament of being made by following raw materials by weight percent:
Radix Rhodiolae extract 75%; Folium Ginkgo 25%.
Its preparation method is that technology extracts the active ingredient of Folium Ginkgo routinely, adds Radix Rhodiolae extract, adds conventional pharmaceutic adjuvant again, makes tablet according to a conventional method.
Embodiment 11.A kind of Chinese medicine composition, it is the medicament of being made by following raw materials by weight percent: Radix Rhodiolae extract 20%; Wherein, rhodioside, butyl alcohol content in Radix Rhodiolae extract is 10%; Folium Ginkgo extract 80%; Folium Ginkgo extract contains Ginkgo total flavones, bilobalide, and wherein bilobalide content in Folium Ginkgo extract is 6%.Its preparation method is, adds conventional pharmaceutic adjuvant, makes pill according to a conventional method.
Embodiment 12.A kind of Chinese medicine composition, it is the medicament of being made by following raw materials by weight percent: Radix Rhodiolae extract 40%; Wherein, rhodioside, butyl alcohol content in Radix Rhodiolae extract is 50%; Folium Ginkgo extract 60%; Folium Ginkgo extract contains Ginkgo total flavones, bilobalide, and wherein bilobalide content in Folium Ginkgo extract is 90%.Its preparation method is, adds conventional pharmaceutic adjuvant, makes oral liquid according to a conventional method.
Embodiment 13.A kind of Chinese medicine composition, it is the medicament of being made by following raw materials by weight percent: Radix Rhodiolae extract 60%; Wherein, rhodioside, butyl alcohol content in Radix Rhodiolae extract is 30%; Folium Ginkgo extract 40%; Folium Ginkgo extract contains Ginkgo total flavones, bilobalide, and wherein bilobalide content in Folium Ginkgo extract is 30%.
Embodiment 14.A kind of Chinese medicine composition, it is the medicament of being made by following raw materials by weight percent: Radix Rhodiolae extract 80%; Wherein, rhodioside, butyl alcohol content in Radix Rhodiolae extract is 65%; Folium Ginkgo extract 20%; Folium Ginkgo extract contains Ginkgo total flavones, bilobalide, and wherein bilobalide content in Folium Ginkgo extract is 95%.
Embodiment 15.A kind of Chinese medicine composition, it is the medicament of being made by following raw materials by weight percent: Radix Rhodiolae extract 95%; Wherein, rhodioside, butyl alcohol content in Radix Rhodiolae extract is 80%; Folium Ginkgo extract 5%; Folium Ginkgo extract contains Ginkgo total flavones, bilobalide, and wherein bilobalide content in Folium Ginkgo extract is 98%.
Embodiment 16.A kind of Chinese medicine composition, it is the medicament of being made by following raw materials by weight percent: Radix Rhodiolae extract 65%; Wherein, rhodioside, butyl alcohol content in Radix Rhodiolae extract is 40%; Folium Ginkgo extract 35%; Folium Ginkgo extract contains Ginkgo total flavones, bilobalide, and wherein bilobalide content in Folium Ginkgo extract is 12%.
Embodiment 17.A kind of Chinese medicine composition, it is the medicament of being made by following raw materials by weight percent:
Radix Rhodiolae 10%; Folium Ginkgo 90%.
Its preparation method is that technology is extracted its active ingredient routinely, adds conventional pharmaceutic adjuvant, makes tablet according to a conventional method, is used for the treatment of alzheimer disease.
Embodiment 18.A kind of Chinese medicine composition, it is the medicament of being made by following raw materials by weight percent:
Radix Rhodiolae 30%; Folium Ginkgo 70%.
Its preparation method is that technology is extracted its active ingredient routinely, adds conventional pharmaceutic adjuvant, makes capsule according to a conventional method, is used for the treatment of tumor.
Embodiment 19.A kind of Chinese medicine composition, it is the medicament of being made by following raw materials by weight percent:
Radix Rhodiolae 70%; Folium Ginkgo 30%.
Its preparation method is that technology is extracted its active ingredient routinely, adds conventional pharmaceutic adjuvant, makes soft capsule according to a conventional method, is used for the treatment of tumor.
Experimental example 1.Be the effect experiment that the inventor did below.
Experiment purpose: discussion group's compound oral capsule (the following A capsule that all claims) is to the protective effect of hemorrhagic shock mice.
Experimental technique: ICR mice random packet, 20 every group.Normal control group (normal saline 20ml.kg
-1, ig.), model control group (normal saline 20ml.kg
-1, ig.), SHENGMAI JIAONANG group (0.6g.kg
-1, ig.), A capsule small dose group (8g crude drug .kg
-1, ig..), (the 16g crude drug .kg of dosage group in the A capsule
-1, ig.), the heavy dose of group of A capsule (32g crude drug .kg
-1, ig.).Behind the 30min, rapidly cut off skin of chest and breastbone behind the broken end, open the thoracic cavity and reveal heart, record breaks end to the time that ventricle stops jumping and is the hemorrhagic shock time, the results are shown in Table.
Experimental result: the A capsule can obviously prolong the mice broken end back heartbeat time.This shows that it can reduce myocardial oxygen consumption, thereby ischemic myocardial is shielded.
The protective effect of table 1 pair hemorrhagic shock mice
| Group | Number of animals (only) | The heartbeat time (s) |
| The heavy dose of group of dosage group A capsule in the normal control group SHENGMAI JIAONANG group A capsule small dose group A capsule | 10 10 10 10 10 | 8.1±1.3 12.3±2.1 ** 12.7±1.5 ** l3.5±1.3 ** 14.2±1.4 ** |
*Compare with the normal control group p＜0.01.
Experimental example 2.The A capsule causes the protective effect experiment of mouse cardiac muscle damage to virus.
Experiment purpose: inquire into the A capsule causes the mouse cardiac muscle damage to virus protective effect.
Experimental technique: with the close Mus cardiac muscle strain CVB of Woodruffs cultivation
3Purification liquid 1.0 * 10
7Pfu/ml lumbar injection 6-8 age in week, male BALB-C mice was made chmice acute myocarditis model.10 of normal control groups, injecting normal saline 0.4ml.With each 10 of infecting mouse random packet, raise in infecting chamber, model control group (normal saline 20ml.kg
-1, ig.), SHENGMAI JIAONANG group (0.6g.kg
-1, ig.), A capsule small dose group (8g crude drug .kg
-1, ig.), (the 16g crude drug .kg of dosage group in the A capsule
-1, ig.), the heavy dose of group of A capsule (32g crude drug .kg
-1, ig.).More than 8 groups of equal successive administrations and observe 12d, during this dying mice is in time put to death, get hematometry SOD in serum concentration and concentration of oxygen free radicals, and the dirty routine pathology inspection of carrying out of coring, respectively organize the survivor to 12d and all put to death and do the same inspection.
Experimental result:
Obviously rising of mouse death rate after the modeling, inflammatory cell infiltration and necrosis are obvious, activity of SOD in serum is starkly lower than normal group, and activity keto concentration has statistical significance (P＜0.01) apparently higher than normal group.Each treatment group infects back mortality rate decline, cardiac muscular tissue's inflammatory cell infiltration and necrosis and all obviously is lighter than not treatment group, all can obviously improve activity of SOD in serum, reduces serum active oxygen concentration (p＜0.01).The results are shown in Table.
Table 2 pair virus causes the influence of mouse cardiac muscle damage mortality rate
| Group | Number of animals (only) | Death toll | Mortality rate (%) |
| The heavy dose of group of dosage group A capsule in the normal control group model matched group SHENGMAI JIAONANG group A capsule small dose group A capsule | 10 10 10 10 10 10 | 0 9 4 3 2 1 | 0 90 △△ 40 ** 30 ** 20 ** 10 ** |
*Compare with model group p＜0.01;
△ △Compare with the normal control group p＜0.01.
Table 3 pair virus causes the influence of mouse cardiac muscle histopathology
| Group | Number of animals (only) | The necrosis region number | Inflammatory infiltration kitchen range number |
| The heavy dose of group of dosage group A capsule in the normal control group model matched group SHENGMAI JIAONANG group A capsule small dose group A capsule | 10 10 10 10 10 10 | 0±0 20.7±11.2 △△ 11.8±4.3 ** 10.4±6.3 ** 10.0±6.0 ** 7.4±2.6 ** | 0±0 18.2±10.0 △△ 9.6±7.9 ** 8.3±3.6 ** 7.5±4.2 ** 6.3±5.2 ** |
*Compare with model group p＜0.01;
△ △Compare with the normal control group p＜0.01.
Table 4 pair virus causes the influence of SOD in Mice activity and activity keto concentration
| Group | Number of animals (only) | The SOD activity | Activity keto concentration |
| Normal control group model matched group SHENGMAI JIAONANG group | 10 10 10 | 211.54±20.68 50.45±12.11 △△ 70.46±15.43 ** | 1142.89±1101.75 2870.13±157.22 △△ 1489.57±172.38 ** |
| The heavy dose of group of dosage group A capsule in the A capsule small dose group A capsule | 10 10 10 | 75.41±12.88 ** 78.47±19.66 ** 81.75±16.67 ** | 1371.55±126.12 ** 1245.27±164.56 ** 1172.67±142.388 ** |
*Compare with model group p＜0.01;
△ △Compare with the normal control group p＜0.01.
Experiment shows that the A capsule causes the mouse cardiac muscle damage to virus and has the certain protection effect.
Experimental example 3.The A capsule is to the therapeutical effect experiment of the tentative pulmonary heart disease of rabbit.
Experiment purpose: inquire into A, B capsule therapeutical effect to the tentative pulmonary heart disease of rabbit.
Experimental technique: animal is divided into normal control group (normal saline 10ml.kg at random
-1, ig.), model control group (normal saline 1ml.kg
-1, ig.), SHENGMAI JIAONANG group (0.1 g.kg
-1, ig.), A capsule small dose group (1g crude drug .kg
-1, ig.), (the 2g crude drug .kg of dosage group in the A capsule
-1, ig.), the heavy dose of group of A capsule (4g crude drug .kg
-1, ig.).Below respectively organize equal successive administration and observed for 4 weeks, all the other are respectively organized continuous auricular vein and inject 1% liquor ferri trichloridi (25ml/ day) except that the normal control group simultaneously.4 weeks back execution animal, light microscopic is drawn materials, and checks with the OptonEM-109 transmission electron microscope.
Experimental result:
The matched group heart, lung, spleen, adrenal gland, thyroid all are the normal structure structure; Model group cardiac muscle sarolemma is unclear, and glycogen reduces, mitochondrion degeneration and interstitial edema; The alveolar epithelial cells degeneration, mitochondrion degeneration, small artery endotheliocytic swelling, interstitial collagen fibroplasia and degeneration; The liver nuclear chromatin is sparse, Golgi complex and endoplasmic reticulum degeneration; The splenocyte degeneration, erythrocyte hemolysis; Renal corpuscle blood capillary, podocyte and vascular endothelial cell degeneration; The degeneration of adrenal gland's entoplastic cells born of the same parents device; The thyroid cell degeneration.The A capsule is respectively organized each internal organs and all rarely seen slight degeneration of gland structure, and significant protective effect is arranged.The SHENGMAI JIAONANG group is light than model group.But attach most importance to than the A Capsules group.
Experiment shows the thing A capsule of the present invention therapeutical effect certain to having of the tentative pulmonary heart disease of rabbit.
Claims (6)
1, a kind of Chinese medicine composition is characterized in that, it is the medicament of being made by following raw materials by weight percent:
Radix Rhodiolae or Radix Rhodiolae extract 1%～99%;
Folium Ginkgo or Folium Ginkgo extract 99%～1%.
2, a kind of Chinese medicine composition according to claim 1 is characterized in that, rhodioside, butyl alcohol content in Radix Rhodiolae extract is not less than 10% in the Radix Rhodiolae extract.
3, a kind of Chinese medicine composition according to claim 2 is characterized in that, rhodioside, butyl alcohol content in Radix Rhodiolae extract is not less than 50% in the Radix Rhodiolae extract.
4, a kind of Chinese medicine composition according to claim 3 is characterized in that, Folium Ginkgo extract contains Ginkgo total flavones, bilobalide, and wherein bilobalide content in Folium Ginkgo extract is not less than 6%.
5, a kind of Chinese medicine composition according to claim 4 is characterized in that, wherein, bilobalide content in Folium Ginkgo extract is not less than 90%.
6, the purposes of any one described Chinese medicine composition in the medicine of preparation treatment alzheimer disease, apoplexy, angina pectoris, diabetic microvascular complication, viral myocarditis, infectious hepatitis and tumor among the claim 1-5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2005101228228A CN1977878A (en) | 2005-11-29 | 2005-11-29 | Chinese medicine composition and its use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2005101228228A CN1977878A (en) | 2005-11-29 | 2005-11-29 | Chinese medicine composition and its use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1977878A true CN1977878A (en) | 2007-06-13 |
Family
ID=38129296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2005101228228A Pending CN1977878A (en) | 2005-11-29 | 2005-11-29 | Chinese medicine composition and its use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1977878A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010119346A2 (en) * | 2009-04-17 | 2010-10-21 | Integrated Chinese Medicine Holdings Ltd. | Herbal compositions and methods for enhancing vital energy and athletic performance |
| CN103271978A (en) * | 2013-05-27 | 2013-09-04 | 浙江万邦药业股份有限公司 | Ginkgo leaf compound preparation for resisting oxygen deprivation and glucose deprivation and treating altitude sickness |
| CN103479743A (en) * | 2013-01-28 | 2014-01-01 | 钱昌美 | Pharmaceutical composition for treating senile dementia and preparation method thereof |
| CN103989723A (en) * | 2014-06-17 | 2014-08-20 | 史克勇 | Drug for treating myocardial ischemia |
| CN105482129A (en) * | 2010-09-30 | 2016-04-13 | 黄奇英 | Anti-cancer extract and compounds |
| CN107823212A (en) * | 2017-10-19 | 2018-03-23 | 中国人民解放军第四军医大学 | Application of the rhodioloside in preventing and treating diabetic vascular damage |
-
2005
- 2005-11-29 CN CNA2005101228228A patent/CN1977878A/en active Pending
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7906159B2 (en) | 2008-04-17 | 2011-03-15 | Vivien Chou | Herbal compositions and methods for enhancing vital energy and athletic performance |
| US8119170B2 (en) | 2008-04-17 | 2012-02-21 | Wen Hsien Chou | Herbal compositions and methods for enhancing vital energy and athletic performance |
| WO2010119346A2 (en) * | 2009-04-17 | 2010-10-21 | Integrated Chinese Medicine Holdings Ltd. | Herbal compositions and methods for enhancing vital energy and athletic performance |
| WO2010119346A3 (en) * | 2009-04-17 | 2010-12-02 | Integrated Chinese Medicine Holdings Ltd. | Herbal compositions and methods for enhancing vital energy and athletic performance |
| CN105482129A (en) * | 2010-09-30 | 2016-04-13 | 黄奇英 | Anti-cancer extract and compounds |
| CN105482129B (en) * | 2010-09-30 | 2018-07-27 | 黄奇英 | Anti-cancer extract and compound |
| CN103479743A (en) * | 2013-01-28 | 2014-01-01 | 钱昌美 | Pharmaceutical composition for treating senile dementia and preparation method thereof |
| CN103479743B (en) * | 2013-01-28 | 2015-07-08 | 钱昌美 | Pharmaceutical composition for treating senile dementia and preparation method thereof |
| CN103271978A (en) * | 2013-05-27 | 2013-09-04 | 浙江万邦药业股份有限公司 | Ginkgo leaf compound preparation for resisting oxygen deprivation and glucose deprivation and treating altitude sickness |
| CN103271978B (en) * | 2013-05-27 | 2015-05-13 | 万邦德制药集团股份有限公司 | Ginkgo leaf compound preparation for resisting oxygen deprivation and glucose deprivation and treating altitude sickness |
| CN103989723A (en) * | 2014-06-17 | 2014-08-20 | 史克勇 | Drug for treating myocardial ischemia |
| CN107823212A (en) * | 2017-10-19 | 2018-03-23 | 中国人民解放军第四军医大学 | Application of the rhodioloside in preventing and treating diabetic vascular damage |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1977878A (en) | Chinese medicine composition and its use | |
| CN104138377A (en) | A pharmaceutical composition treating severe high-altitude diseases | |
| CN104587087A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases | |
| CN1977890B (en) | Chinese medicine composition and its use | |
| CN1803787B (en) | Hypericum perforatum L. total flavone extracts, its preparation and application | |
| CN100569234C (en) | Ginkgo total lactone composition with neuroprotective | |
| CN102743424A (en) | Flos chrysanthemi indici effective ingredient and application thereof | |
| CN106668564B (en) | Natural medicine composition for improving memory function | |
| CN109045035A (en) | Application of 7- (2,2- dimethyl -3- crotonoyl the amido)-octahydro benzene quinoline acetic acid esters in preparation treatment liver disease drug | |
| Sailor et al. | Platelet augmentation potential of polyherbal formulation in cyclophosphamide-induced thrombocytopenia in wistar rats | |
| CN101181285A (en) | Application of astragaloside IV in the preparation of medicament for curing nervus retrogression disease | |
| CN105012356B (en) | Purposes of the ganoderic acid A in depression | |
| CN100431562C (en) | Chinese traditional medicinal preparation containing red sange root and safflower for treating cardiovascular and cerebrovascular diseases and preparing process thereof | |
| CN102462710A (en) | Application of sunset abelmoschus flower total flavone to preparation of medicament for preventing and treating hepatofibrosis | |
| CN102579530A (en) | Preparation method of aralia taibaiensis total saponin having diabetes mellitus resisting effect and medicament | |
| CN102813907B (en) | Medicine composition for treating cerebrovascular accident sequela and preparation method and application thereof | |
| CN102125662A (en) | Compound traditional Chinese medicine for treating apoplexia and preparation method and application thereof | |
| CN102100833B (en) | Drug composition for treating heart cerebrovascular diseases as well as preparation method and application thereof | |
| WO2017121333A1 (en) | Use of cistanche tubulosa extract and isoacteoside in protection of muscles | |
| CN107753823A (en) | A kind of Chinese medicine composition for treating or preventing hand-foot-and-mouth disease | |
| CN100457140C (en) | Pharmaceutical composition containing lamivudine | |
| CN102188477A (en) | Preparation method and application of active component of radix gentianae extractive | |
| CN108210879A (en) | A kind of pharmaceutical composition for treating acute Cerebral bleeding and its application | |
| CN106344549A (en) | Application of rhein in preparation of drugs for preventing and/or treating hand-foot-and-mouth disease | |
| CN112007058A (en) | Application of oroxylum indicum as antioxidant stress injury agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20070613 |